Intellia Therapeutics, Inc.

NTLA · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.8%

Institutions99.9%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$67.67M	$57.88M	$52.12M	$33.05M	$57.99M	$43.10M	$30.43M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$440.99M	-$534.26M	-$458.16M	-$267.85M	-$136.58M	-$106.37M	-$90.87M	-$69.56M	-$32.16M
Operating income as a percentage of revenue.	-651.7%	-923.1%	-879.0%	-810.4%	-235.5%	-246.8%	-298.6%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$412.69M	-$519.02M	-$474.19M	-$267.89M	-$134.23M	-$99.53M	-$85.34M	-$67.54M	-$31.63M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.81	$-5.25	$-6.16	$-3.78	$-2.40	$-2.11	$-1.00	$-1.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.81	$-5.25	$-6.16	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$155.46M	$189.18M	$523.51M	$123.41M	$160.02M	$57.23M	$58.86M	$340.68M	$273.06M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$842.13M	$1.19B	$1.52B	$1.29B	$676.32M	$334.28M	$347.31M	$376.24M	$298.97M
Everything the company owes — debt, unpaid bills, and other obligations.	$170.73M	$319.06M	–	–	–	–	–	–	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$671.39M	$871.96M	$1.24B	$1.04B	$527.07M	$269.88M	$277.92M	$300.60M	$209.84M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$394.74M	-$348.88M	-$333.29M	-$225.03M	-$49.91M	-$103.24M	-$61.26M	-$65.28M	$36.11M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.13M	$5.78M	$13.56M	$12.76M	$3.58M	$6.79M	$6.36M	$10.09M	$6.17M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$395.87M	-$354.66M	-$346.85M	-$237.79M	-$53.50M	-$110.03M	-$67.61M	-$75.37M	$29.94M

	You	Peer avg
Revenue Growth	-46.2%	-0.3%
ROE	-55.4%	-118.3%

Intellia Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison